Translational Session
Have We Fully Exploited the Potential of SGLT2 Inhibitors for the Treatment of CKD?
November 09, 2025 | 09:30 AM - 11:30 AM
Location: Room 361A, Convention Center
Session Description
Four major kidney outcome trials have demonstrated the clinical benefit of SGLT2 inhibitors in patients with CKD with and without diabetes. However, SGLT2 inhibitors are not indicated for all patients with CKD. For example, patients with PKD, patients on dialysis, or those living with a kidney transplant were excluded from the major outcome trials. This session reviews the potential role of SGLT2 inhibitors for patients with CKD for whom these drugs are currently not indicated.
Learning Objective(s)
- Describe the mechanism of action of SGLT2 inhibitors in patients with severe kidney diseases
- Assess the potential of SGLT2 inhibitors to slow disease progression in patients with PKD
- Explain why SGLT2 inhibitors may be beneficial in patients receiving dialysis or living with a kidney transplant
Learning Pathway(s)
- CKD Non-Dialysis
- Pharmacology
Moderators
Presentations
- Mechanism of Organ Protection with SGLT2 Inhibitors Beyond the SGLT2 Transporter
09:30 AM - 10:00 AM
- Effects of SGLT2 Inhibitors in Patients Receiving a Kidney Transplant or Dialysis
10:00 AM - 10:30 AM
- Are SGLT2 Inhibitors Safe and Effective in Patients with PKD?
10:30 AM - 11:00 AM
- Can We Use SGLT2 Inhibitors in Patients with Type 1 Diabetes and CKD?
11:00 AM - 11:30 AM